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Hundreds of millions of cases of malaria occur
annually, and infections with Plasmodium
falciparum, the most virulent human malaria
parasite, cause more than one million deaths per
year (1). Despite extensive control efforts, the
incidence of the disease is not decreasing in most
malaria-endemic areas of the world, and in some
it is clearly increasing (2). Malaria also remains a
major risk to travelers from industrialized to
developing countries. Because malaria parasites
are increasingly resistant to antimalarial drugs,
appropriately counseled travelers to malaria-
endemic regions are more likely to contract
malaria now than they were 40 years ago.
Malaria control efforts include attempts to
develop an effective vaccine, eradicate mosquito
vectors, and develop new drugs (2,3). However,
the development of a vaccine has proven very
difficult, and a highly effective vaccine will
probably not be available in the near future (4).
Efforts to control Anopheles mosquitoes have had
limited success, although the use of insecticide-
impregnated bed nets does appear to reduce
malaria-related death rates (5). In addition,
methods to replace natural vector populations
with mosquitoes unable to support parasite
development are under study and may contribute
to malaria control in the long term (6). However,
the current limitations of vaccine and vector
control, as well as the increasing resistance of
malaria parasites to existing drugs, highlight the
continued need for new antimalarial agents.
Established Antimalarial Drugs
Antimalarial drugs have been used for
centuries. Early natural products, including the
bark of the cinchona tree in South America and
extracts of the wormwood plant in China, were
among the first effective antimicrobial agents to
be used. Cinchona bark was used in Europe
beginning in the 17th century, and upon its
isolation from bark in 1820, quinine became
widely used. In the last 50 years, extensive efforts,
including the screening of hundreds of thousands
of compounds, have led to the development of a
number of effective synthetic antimalarial drugs.
The most important of these, chloroquine, has
been the mainstay of antimalarial chemotherapy
for the last 50 years. The compound eradicates
parasites rapidly, has minimal toxicity, is widely
available at low cost throughout the world, and
needs to be taken only once a week for
chemoprophylaxis. However, resistance to chloro-
quine has been steadily increasing since the
drug’s initial use in South America and Southeast
Asia in the late 1950s. Chloroquine resistance is
now widespread in most P. falciparum-endemic
areas of the world (3). Thus, the use of chloroquine
for presumptive treatment of falciparum malaria
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or for chemoprophylaxis is usually no longer
appropriate (7). Moreover, resistance to chloro-
quine of P. vivax, the second most lethal human
malaria parasite, is increasing in South Asia (8).
No other antimalarial drug (9-12) is as
efficacious and safe as chloroquine (Table 1). The
best antimalarial drug for treating chloroquine-
resistant falciparum malaria remains quinine (or
intravenous quinidine), which is fairly toxic;
quinine resistance is increasing in Southeast
Asia, particularly in the border areas of Thailand
(9). Amodiaquine, used to treat chloroquine-
resistant malaria in developing countries, is also
quite toxic, and resistance to it is also common
(13). Mefloquine (14) is widely used for
chemoprophylaxis against chloroquine-resistant
P. falciparum, but its use is limited by toxicity (15)
and (in the developing world) high cost. Mefloquine
is not approved for treatment of malaria in the
United States because of the neurotoxicity of
doses required for the treatment. Fansidar, a
combination of sulfadoxine and pyrimethamine,
is no longer recommended for chemoprophylaxis
because of its dermatologic toxicity (15). Fansidar
is also not an ideal drug for treatment because it is
slow acting, but it is increasingly important in
treating chloroquine-resistant malaria  in developing
countries because  economic constraints limit the
use of other agents (16). The use of both
mefloquine and Fansidar will increasingly be
limited by drug resistance, already widespread in
parts of Southeast Asia (9,17).
Other antimalarial drugs have specialized
uses. Tetracyclines and some other antibiotics
(clindamycin, sulfas) are slow acting and
generally best used as an adjunct to quinine
therapy in treating falciparum malaria (9).
Doxycycline is also used for chemoprophylaxis in
regions with high levels of drug resistance,
especially Southeast Asia (10,17). Other drugs for
chemoprophylaxis include proguanil, which
remains effective in combination with chloro-
quine in many areas other than Southeast Asia,
and Maloprim, a combination of dapsone and
pyrimethamine (10,17). Resistance to these drugs
is fairly common, however. Primaquine has a
well-defined specific role: eradicating chronic
liver stages of P. vivax and P. ovale after treating
the acute blood infection with chloroquine.
New Antimalarial Drugs
Relatively few new antimalarial drugs are
undergoing clinical testing (Table 2). Halofantrine,
identified in the 1940s, was not developed until
Table 1. Established antimalarial drugsa
Drug Role Best Feature(s) Limitations
Chloroquine TX of and CP against non- Very safe; low Widespread R
  Pf and sensitive Pf parasites   cost; long half-life
Quinine/quinidine Best TX  for Pf malaria; Limited R; Fairly toxic (cinchonism,
  low cost   rapidly acting   cardiac)
Amodiaquineb TX of R Pf malaria Low cost Toxicity (bone marrow,
  liver); R common
Mefloquine CP against R Pf malaria; Relatively little R, Moderately toxic
  not approved for TX   though increasing;   (mostly CNS); high
  in United States   long half-life   cost; R in SE Asia
Fansidar TX of Pf malaria; no longer Relatively low cost; Skin toxicity (can be
  recommended for CP   long half-life   fatal); increasing R
Primaquine Eradication of chronic Only drug for this Hemolysis with G6PD
  liver stage Pv, Po malaria   indication   deficiency; increasing R
Proguanilb CP only (often with Low cost; nontoxic R common
  chloroquine)
Maloprimb CP only (often with Low cost R common; skin rashes
  chloroquine)
Tetracyclines CP; TX of Pf malaria in Low cost Skin and gastrointes-
  combination with quinine   tinal toxicity
aTX, therapy; CP, chemoprophylaxis; R, resistance/resistant; Pf, Plasmodium falciparum; Pv, P. vivax; Po, P. ovale; CNS, central
nervous system; G6PD, glucose 6-phosphate dehydrogenase.
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the 1980s; its use has been limited by variable oral
absorption and cardiac toxicity (12,18). The drug
is approved in the United States for treatment of
chloroquine-resistant  P. falciparum infection,
although in most cases quinine (or intravenous
quinidine) is preferable. The most effective new
drugs are artemisinin and related compounds.
Artemisinin was isolated in 1972 from Artemisia
annua, a plant used in China for centuries to treat
fever (19). Artemisinin derivatives (artesunate,
artelinate, artemether, arteether, dihydroartemisinin)
have been synthesized and are undergoing
extensive clinical testing. These compounds, which
are already widely used in some areas, are potent,
rapidly acting antimalarials that are effective
against chloroquine-resistant P. falciparum (20).
Because recrudescences of infection after treat-
ment are common, however, artemisinin and
related compounds might best be used in
combination with another drug.
Other compounds are under evaluation.
Atovaqone (21), which  is approved for treating
patients with Pneumocystis infections, appears
to be effective against malaria in combination
with proguanil (22), but its use has been limited
by recrudescence after treatment. Pyronaridine,
an acridine derivative used to treat malaria in
China, has shown efficacy against falciparum
malaria (23). The iron chelator desferrioxamine
enhances the clearance of parasites in mild
malaria (24) and, in conjunction with quinine
and Fansidar, hastens recovery from deep coma
in severe falciparum malaria (25). Azithromycin,
a quinolone antibiotic, appears efficacious in
malaria chemoprophylaxis (26).
Malarial Proteases: New Targets for
Chemotherapy
The limitations of antimalarial chemotherapy
underscore the need for new drugs, ideally
directed against new targets. Potential targets for
chemotherapy include malarial proteases (27).
The erythrocytic life cycle, which is responsible for
all clinical manifestations of malaria, begins when
free merozoites invade erythrocytes. The
intraerythrocytic parasites develop from small
ring-stage organisms to larger, more metaboli-
cally active trophozoites and then to multi-
nucleated schizonts. The erythrocytic cycle is
completed when mature schizonts rupture
erythrocytes, releasing numerous invasive mero-
zoites. Proteases appear to be required for the
rupture and subsequent reinvasion of erythro-
cytes by merozoite-stage parasites and for the
degradation of hemoglobin by intraerythrocytic
trophozoites (Figure).
Proteases and Erythrocyte Rupture and
Invasion
The rupture of erythrocytes by mature
schizonts and the subsequent invasion of
erythrocytes by free merozoites appear to require
malarial protease activity, possibly to breach the
erythrocyte cytoskeleton, a complex network of
proteins. In addition, a number of malarial
proteins are proteolytically processed during the
late schizont and merozoite life-cycle stages; for
example, merozoite surface protein-1 is processed
in a manner inhibited by serine protease
inhibitors (28), presumably to facilitate the
complex series of events involved in erythrocyte
Table 2. New antimalarial drugs
Drug Role Best Feature(s) Limitations
Halofantrine TX of Pf malaria; not Usually effective Variable bioavailability,
  approved for CP   against R Pf malaria   cardiac toxicity
Artemisinin and TX of Pf malaria Rapidly acting; effec- Recurrence after TX fairly
  related compoundsa   tive against multidrug-R   common
  strains
Atovaquone ? TX of Pf malaria; ? Limited toxicity Limited studies so far show
  CP (probably in combi-   frequent recurrence after TX
  nation with proguanil)
Pyronaridinea ? TX of Pf malaria Effective against R strains Studies limited to date
Desferrioxamine ? TX of severe Pf Well tolerated when Studies limited to date
  malaria   used for iron overload
Azithromycin ? CP Limited toxicity Studies limited to date
For abbreviations, see Table 1, footnote a.
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rupture and invasion (29). Although the specific
roles of different classes of proteases are not
completely clear, inhibitors of cysteine and serine
proteases have consistently blocked erythrocyte
rupture and invasion (27).
Candidate  P. falciparum rupture/invasion
proteases have been identified, but none has been
fully characterized biochemically or molecularly:
1) a 68 kD cysteine protease was identified in
schizonts and merozoites and localized to the
merozoite apex, suggesting that it may be
released from the rhoptry organelle during
invasion (30); 2) a cysteine protease of mature
schizonts and a serine protease of merozoites
were identified in highly synchronized parasites
(31); 3) a serine protease was shown to be bound to
the schizont/merozoite membrane by a glycosyl-
phosphatidylinositol anchor, to be activated by
phosphatidylinositol-specific phospholipase C
during the merozoite stage, and to be capable of
cleaving the erythrocyte cytoskeletal protein
band 3 (32,33); 4) another protease, inhibited by
both cysteine and serine protease inhibitors,
hydrolyzed the erythrocyte cytoskeletal proteins
spectrin and band 4.1 (34); and 5) the serine
repeat antigen (35,36) and the related protein
SERP H (37), both expressed in mature
schizonts, have important similarities in their
sequences with cysteine proteases. Further
research should identify the specific biologic
roles of the proteases mentioned and better
characterize these enzymes, thus fostering the
development of specific inhibitors.
Host proteases may also play a role in
erythrocyte rupture by P. falciparum. In recent
studies, host urokinase was shown to bind to the
surface of P. falciparum-infected erythrocytes,
and the depletion of urokinase from parasite
culture medium inhibited erythrocyte rupture by
mature schizonts (38). This inhibition was
reversed by exogenous urokinase.
Drug Development Efforts
Synthetic peptide inhibitors of the P.
falciparum schizont cysteine protease Pf 68
inhibited erythrocyte invasion by cultured
parasites (39,40). The most effective peptide,
GlcA-Val-Leu-Gly-Lys-NHC2H5, inhibited the
protease and blocked parasite development at
high micromolar concentrations (40; Table 3).
Although these results do not demonstrate levels
of inhibition expected to be therapeutically
relevant, they suggest that a specific protease
activity is required for erythrocyte invasion by
malaria parasites and thus is a potential target for
antimalarial drugs.
Proteases and Malarial Hemoglobin
Degradation
Extensive evidence suggests that the degra-
dation of hemoglobin is necessary for the growth
of erythrocytic malaria parasites, apparently to
provide free amino acids for parasite protein
synthesis (27,50). In P. falciparum, hemoglobin
degradation  occurs predominantly in trophozoites
and early schizonts, the stages at which the
parasites are most metabolically active. Tropho-
zoites ingest erythrocyte cytoplasm and transport
it to a large central food vacuole. In the food
vacuole, hemoglobin is broken down into heme, a
major component of malarial pigment (51), and
globin, which is hydrolyzed to its constituent amino
acids. The food vacuole is an acidic organelle
analogous to lysosomes. Several lysosomal pro-
teases are well characterized, including cysteine
(cathepsins B, H, and L) and aspartic (cathepsin D)
proteases (52), and malaria parasites contain
analogous food vacuole proteases that degrade
hemoglobin. At least two aspartic proteases and
one cysteine protease have been isolated from
purified  P. falciparum food vacuoles (53).
Malarial aspartic protease activities have
been identified (54-60). Two recently character-
ized aspartic proteases (plasmepsin I and
Figure. Protease targets in erythrocytic malaria
parasites. The Plasmodium falciparum erythrocytic
life cycle is shown schematically, and data supporting
cysteine (CP), serine (SP), and aspartic (AP) proteases
of the different parasite stages as chemotherapeutic
targets are provided in italics.53 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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plasmepsin II) are located in the food vacuole, have
acid pH optima, and share sequence homology with
other aspartic proteases (41,53,61,62). Further-
more, the aspartic proteases can cleave hemoglo-
bin. One of the enzymes, plasmepsin I, cleaves
native hemoglobin (53,59). Plasmepsin II appears
to prefer denatured globin as a substrate (53). On
the basis of these data, plasmepsin I is thought to be
responsible for initial cleavages of hemoglobin after
the molecule is transported to the food vacuole (53).
Incubation of cultured P. falciparum para-
sites with the protease inhibitor leupeptin caused
trophozoite food vacuoles to fill with apparently
undegraded erythrocyte cytoplasm (63-65). Analy-
sis of the leupeptin-treated parasites showed that
they contained large quantities of undegraded
globin, while minimal globin was detectable in
control parasites (64,66). Leupeptin inhibits both
cysteine and some serine proteases, but the highly
specific cysteine protease inhibitor E-64 also
caused undegraded globin to accumulate. After
parasites were incubated with inhibitors of other
classes of proteases including the aspartic
protease inhibitor pepstatin (63-67), globin did
not accumulate. More recent studies that used
nondenaturing electrophoretic methods demon-
strated that cysteine protease inhibitors not only
blocked malarial globin hydrolysis, but also
inhibited earlier steps in hemoglobin degrada-
tion, including denaturation of the hemoglobin
tetramer and the release of heme from globin (68).
Another study showed that E-64, but not
pepstatin, inhibited the production of hemozoin
(the malarial end product of heme) by cultured
parasites (69). These results suggest that a
cysteine protease is required for initial steps in
hemoglobin degradation by P. falciparum.
A P. falciparum trophozoite cysteine protease
with biochemical features expected for a food
vacuole hemoglobinase has been identified (31)
and biochemically (70-72) and molecularly (73)
characterized. This protease, called falcipain,
degraded denatured and native hemoglobin in
vitro; its acid pH optimum, substrate specificity,
and inhibitor sensitivity indicated that it was a
papain family cysteine protease (64,70,71).
Specific inhibitors of falcipain blocked hemoglo-
bin degradation and prevented parasite develop-
ment. The degree of inhibition of falcipain by
fluoromethyl ketones (44) and vinyl sulfones (46)
correlated with their inhibition of hemoglobin
degradation and parasite development, support-
ing the hypothesis that falcipain is the cysteine
protease required for hemoglobin degradation.
The specific mechanism for hemoglobin
degradation in the malarial food vacuole remains
unclear. As noted above, both the aspartic
protease plasmepsin I and the cysteine protease
falcipain have been identified in parasite food
vacuoles and shown to cleave denatured and
native hemoglobin in vitro (53,71). Results
showing that only cysteine protease inhibitors
block hemoglobin processing and globin hydroly-
sis in cultured parasites suggest that falcipain is
required for initial steps of hemoglobin degrada-
tion (66-68,74). However, other studies have
Table 3. Protease targets for chemotherapy
Effective inhibitorsa
In vitrob In vivoc
Protease Biologic role Compound  (Reference) (IC50; mM) (mg/kg/day)
Pf68 Erythrocyte invasion GlcA-Val-Leu-Gly-Lys-NHC2H5 (40) 900
Plasmepsin I Hemoglobin degradation SC-50083 (41)     2-5
Ro 40-4388 (42)     0.25
Plasmepsin II Hemoglobin degradation Compound 7 (43)   20
Falcipain Hemoglobin degradation Z-Phe-Arg-CH2F (44)     0.064
Mu-Phe-HPh-CH2F (45)   ~0.03  400
Mu-Leu-HPh-VSPh (46)     0.01
Oxalic bis ((2-hydroxy-1-naph-     7
  thylmethylene)hydrazide) (47)
1-(2,5-dichlorophenyl)-3-     0.23
  (4-quinolinyl)-2-propen-1-one (48)
7-chloro-1,2-dihydro-2-(2,3-di-     2
  methoxy-phenyl)-5,5-dioxide-
  4-(1H,10H)-phenothiazinone (49)
aThe structures of these compounds and details of the described studies are in the references noted.
bAssays compared the development of new ring-form parasites or the uptake of [3H]hypoxanthine by treated and control
parasites.
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shown that native hemoglobin is cleaved by
plasmepsin I, but not falcipain, in nonreducing
conditions that may be present in the food
vacuole (53,59,72). In any event, regardless of the
exact sequence of hemoglobin processing,
multiple enzymes, including at least the three
proteases already identified, appear to partici-
pate in the degradation of hemoglobin. These
proteases are thus logical targets for antimalarial
drug development.
Aminopeptidase activity has also been
described in malaria parasites (75-77). This
activity, with a neutral pH optimum, was not
found in food vacuole lysates (77). When these
lysates were incubated with hemoglobin, discrete
peptide fragments, but not free amino acids, were
identified (77). These results suggest that
hemoglobin is degraded to small peptides in the
food vacuole, that these peptides are transported
to the parasite cytosol, and that additional
processing of hemoglobin peptides is mediated by
cytosolic aminopeptidase activity (77).
Drug Development Efforts
Both the cysteine protease inhibitor E-64 and
the aspartic protease inhibitor pepstatin blocked
P. falciparum development (63-67). Administered
together, the two inhibitors acted synergistically
(67). However, only E-64 blocked globin hydroly-
sis (64-67). Numerous peptide-based cysteine
protease inhibitors, including fluoromethyl ke-
tones (44,70,78) and vinyl sulfones (46), inhibited
falcipain at low nanomolar concentrations and
inhibited P. falciparum development and hemo-
globin degradation at concentrations below 100
nanomolar (Table 3). In a malaria animal model, a
fluoromethyl ketone that inhibited falcipain at
low nanomolar concentrations blocked P. vinckei
protease activity in vivo after a single subcutane-
ous dose, and, when administered for 4 days,
cured 80% of murine malaria infections (45).
Thus, despite the theoretical limitations of
potentially rapid degradation in vivo and inhibition
of host proteases, peptide protease inhibitors show
promise as candidate antimalarial drugs.
Fluoromethyl ketones have subsequently shown
toxicity in animal studies, but evaluations of
related, apparently nontoxic inhibitors of falcipain
as antimalarial drugs are under way.
A computer model for the structure of
falcipain was used to identify nonpeptide
inhibitors (47). Screening of potential nonpeptide
inhibitors identified a low micromolar lead
compound (47; Table 3). Subsequent synthesis and
testing of small molecules based on the structure of
the lead compound have identified biologically
active falcipain inhibitors, including chalcones that
block parasite metabolism at submicromolar
concentrations (48) and phenothiazines that block
parasite metabolism and development at low
micromolar concentrations (49).
Peptidelike aspartic protease inhibitors are
potent inhibitors of plasmepsins I and II. In
independent studies SC-50083 (41), Ro 40-4388
(42), and “compound 7” (43) inhibited plasmepsin
I or II at nanomolar concentrations and blocked
parasite development at high nanomolar to
micromolar concentrations (Table 3). Drug develop-
ment efforts should be assisted by the recent
determination of the structure of plasmepsin II
(43). Inhibitors of aspartic and cysteine proteases
have synergistic effects in inhibiting the growth of
cultured malaria parasites (67), and these
proteases also act synergistically to degrade
hemoglobin in vitro (41). Therefore, the combina-
tion of inhibitors of malarial cysteine and aspartic
proteases may provide the most effective
chemotherapeutic regimen and best limit the
development of parasite resistance to protease
inhibitors. Ultimately, a better understanding of
the biochemical properties and biologic roles of
malarial proteases will foster the development of
protease inhibitors that specifically inhibit
parasite enzymes and thus are the most suitable
candidates for chemotherapy.
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